Central nervous system tuberculosis after resolution of miliary tuberculosis.
Chang
A B
AB
Department of Thoracic Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.
Grimwood
K
K
Harvey
A S
AS
Rosenfeld
J V
JV
Olinsky
A
A
D000995:Antitubercular Agents / Q000627:therapeutic use; D002494:Central Nervous System Infections / Q000175:diagnosis / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005000:Ethionamide / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007121:Immunocompetence; D007223:Infant; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D017211:Treatment Failure; D014375:Tuberculoma / Q000175:diagnosis / Q000188:drug therapy*; D014390:Tuberculosis, Meningeal / Q000188:drug therapy* / Q000503:physiopathology; D014391:Tuberculosis, Miliary / Q000188:drug therapy* / Q000503:physiopathology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D005938:Glucocorticoids; D011718:Pyrazinamide; D003907:Dexamethasone; D011239:Prednisolone; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin